2013 ACR/ARHP Annual Meeting

October 25-30, 2013. San Diego, CA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1667

Serum S100A8/S100A9 and S100A12 As a Marker Of Disease Activity In Giant Cell Arteritis
Abstract Number: 1260

Serum S100β Is Associated With Neuropsychiatric Manifestations In Childhood-Onset Systemic Lupus Erythematosus
Abstract Number: 699

Severity Of Muscle Weakness Predicts Disability In Scleroderma
Abstract Number: 883

Sex Bias In Autoimmune Diseases: Increased Risk Of 47,XXX In Systemic Lupus Erythematosus (SLE) and Sjögren’s Syndrome (SS) Supports The Gene Dose Hypothesis
Abstract Number: 1195

Sex Differences In Gout Evaluation and Management
Abstract Number: 395

Sex Differences In Lean Mass Deficits In Rheumatoid Arthritis
Abstract Number: 2577

Sex Disparities In Survival Of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension and Idiopathic Pulmonary Arterial Hypertension Patients
Abstract Number: 1698

Sex-Related Differences and Trends In Mortality Of Juvenile-Onset Systemic Lupus Erythematosus (SLE) In The United States Over The Last Forty Years, 1971-2010
Abstract Number: 898

Sex-Specific Employment Participation Restriction Across Occupational Groups Among Working-Age (18-64 years) U.S. Adults With and Without Arthritis
Abstract Number: 1932

Shared Decision Making In Early Knee Osteoarthritis: Perspectives Of Older Adults With Overweight and Obesity and Health Care Providers
Abstract Number: 1032

Shared Decision-Making In The Choice Of Biologic Medication: The Patient Perspective
Abstract Number: 2600

Shear Wave Elastography: A Novel Quantitative Approach For Evaluating Scleroderma Skin
Abstract Number: 370

Shift In Cardiovascular Risk and Lipid Levels In Rheumatoid Arthritis Patients Using ATP-3 Guidelines: Corrona Certain Study
Abstract Number: 1750

Short and Long-Term Biological Therapy In Refractory Uveitis Of Behcet’s Syndrome. Multicenter Study Of 124 Patients
Abstract Number: 2169

Short Term Efficacy Of Biologic Agents In Patients With Systemic Juvenile Idiopathic Arthritis: Network Meta-Analysis Of Randomized Trials

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].